Are BBNX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BBNX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / BBNX / insiders

SIBN (52) IRMD (55) IART (19) KIDS (50) ⌘ Pro Terminal →

Beta Bionics Inc. (BBNX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$15.90 -5.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.72

Beta Bionics Inc. (BBNX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $910.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBNX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Beta Bionics Inc. (NASDAQ: BBNX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.90 (-5.07% 1D, market cap $910.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BBNX ranks #563 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBNX compare to SIBN and IRMD in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), BBNX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 55.4%, and ROIC of -22.1%. By comparison, SIBN (SI-BONE Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M) and IRMD (iRadimed Corporation) posts a D+ grade (55/100 RQD, P/E 48.8x, ROIC 37.7%, cap $980.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBNX?

▼

Per BBNX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674632), Beta Bionics Inc. generated $100.3M in revenue (+53.9% YoY), -$73.2M in net income, and -$56.2M in free cash flow against $328.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.73 (-1.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBNX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY BBNX SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 12.82 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 55.4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$17.69+0.3% Next Q

Q2 (-2Q)

Grade D$17.74+20.6% Next Q

Q3 (-1Q)

Grade E$21.39-25.7% Next Q

Current

Grade D-$15.90-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBNX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBNX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.02) and Max Pain ($16.70) forces dealer call-delta covering toward $34.35.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBNX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BBNX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BBNX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BBNX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BBNX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBNX)

✓Walkthrough of BBNX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BBNX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.58%📐 HORIZONTAL RANGE

2026-11-03O $17.58H $17.58L $15.90C $15.90VOL 1.07M

RES: $27.21SUP: $12.08SMA50: $19.02SMA200: $14.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBNX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBNX Butterfly Map → + Track BBNX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +53.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BBNX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBNX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BBNX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBNX)

Health Care Rank #563 of 1015 ⚔️ SIBN vs BBNX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBNX vs. SIBN, IRMD, IART, KIDS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Beta Bionics Inc. (BBNX) ranks #563 by composite RQD confidence (36/100, grade D-) and #369 by equity capitalization ($910.6M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with BBNX at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BBNX ACTIVE Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-5.07%	$910.6M	Benchmark Subject
SIBN SI-BONE Inc.	D+	52/100	—	79.6%	-10.3%	-4.76%	$951.5M	/sibn-vs-bbnx →
IRMD iRadimed Corporation	D+	55/100	48.8x	76.7%	37.7%	+3.57%	$980.5M	/irmd-vs-bbnx →
IART Integra LifeSciences Holdings Corporation	E	19/100	—	50.9%	-35.0%	+6.75%	$992.0M	/iart-vs-bbnx →
KIDS OrthoPediatrics Corp.	D	50/100	—	73.1%	-7.3%	-1.42%	$806.0M	/kids-vs-bbnx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674632 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Beta Bionics Inc. (BBNX) reported GAAP revenue of $100.3M (+53.9% vs. FY2024 revenue of $65.1M , and +735.8% cumulative change since FY2023) , GAAP net income of -$73.2M, operating cash flow of -$50.9M, and free cash flow of -$56.2M (-8.8% YoY). On the balance sheet, BBNX closed FY2025 with $328.7M in total assets against $0 in total debt (Altman Z-Score: 12.82, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$100.3M	-$73.2M	-$50.9M	-$56.2M	$328.7M	—
FY2024 (FY)	2024-12-31	$65.1M	-$54.8M	-$48.3M	-$51.7M	$149.6M	—
FY2023 (FY)	2023-12-31	$12.0M	-$44.1M	-$32.4M	-$32.4M	—	—

3. BBNX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBNX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BBNX compare to SIBN and IRMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BBNX?

Where is BBNX trading relative to its 50-day, 200-day, and 52-week technical levels?

BBNX last traded at $15.90 (-5.07% on volume of 804,271 shares), positioning the stock -16.40% below its 50-day simple moving average ($19.02) and +7.36% above its 200-day simple moving average ($14.81). Across its 52-week range of $8.80 to $32.71, BBNX sits at the 29.7% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.91 to $17.89).

Direct Sub-Reports: BBNX RQD Cockpit BBNX 12M Forecast BBNX Earnings & Move BBNX Dividends & DRIP BBNX Insiders & 13F BBNX Whale Options BBNX Profit Sankey BBNX News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BBNX — Beta Bionics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Beta Bionics Inc. (BBNX) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.90 (-5.07% 1D, market capitalization $910.6M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -22.1%, gross margin of 55.4%, operating margin of -60.0%, and free cash flow yield of -5.88%.
Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 12.82, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the market data, the company reports a gross margin of 55.4%. — for detailed product lines, customer segments, or revenue model descriptions.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Beta Bionics Inc. (BBNX) reported $100.3M in annual revenue (up from $65.1M in FY2024, +53.9% YoY) and -$73.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.0M revenue, -$44.1M net income) through FY2025, BBNX scaled operating cash flow to -$50.9M and free cash flow to -$56.2M, backed by $328.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.88% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $8.80 – $32.71 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and second-order bottlenecks are — Investors should note that the class action items in the news feed are the only cross-cutting event signals present in the source data.

Key Question #1: Can BBNX sustain or expand its -60.0% operating margin and -22.1% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $100.3M and free cash flow of -$56.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is BBNX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BBNX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Beta Bionics Inc. (BBNX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBNX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 22h ago

Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Yahoo Finance report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 1d ago

Beta Bionics (BBNX) Faces Class Action After 37% Stock Drop

TradingView report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Chief commercial officer Hopman sells $7,015 of Beta Bionics stock

Investing.com report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Morningstar • 1d ago

BBNX UPCOMING DEADLINE: SueWallSt Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the Firm

Morningstar report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Daily Tribune News • 1d ago

BBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the Firm

The Daily Tribune News report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates

Yahoo Finance report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein

GlobeNewswire report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Beta Bionics (BBNX) Stock Looks Expensive Even After Its 43% Fall

Simply Wall St report covering Beta Bionics Inc. (BBNX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBNX Bull vs. Bear Conversation Board — What's Your Call at $15.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBNX 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $20.27 (+21.0%)

📌 Pinned Debate

Revenue scaled from $12.0M in FY 2023 to $100.3M in FY 2025 while the forensic balance sheet scored 11 / 20 with an Altman Z of 12.82.

Revenue scaled from $12.0M in FY 2023 to $100.3M in FY 2025 while the forensic balance sheet scored 11 / 20 with an Altman Z of 12.82.. When you look under the hood at BBNX, Fundamental Cash Engine is 9/20 with 55.4% gross margins and -22.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (6/20) has been quietly accumulating below $32.71. My 12M target is $20.27.

CapAlloc_Nerd 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (55.4%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $12.90 (-23.0%)

Spot @ $16.75

Operating margin of -60% and FCF of -$56.2M in FY 2025, with ROIC at -22.1% and Insider Conviction scored 3 / 20.

Operating margin of -60% and FCF of -$56.2M in FY 2025, with ROIC at -22.1% and Insider Conviction scored 3 / 20.. Look at the math on BBNX: paying current EV/EBITDA multiples for -22.1% ROIC and -60.0% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $14.74 before getting long.